Polynovo (CALZF)

What Moves the Stock

1. 01US market revenue growth rate and hospital account additions (US represents largest addressable market, ~$500M+ opportunity)
2. 02FDA regulatory milestones for expanded indications beyond burns (hernia, breast reconstruction, orthopedic applications)
3. 03Quarterly unit volume growth and average selling price trends across geographies
4. 04Clinical trial results and peer-reviewed publications demonstrating outcomes superiority
5. 05Competitive dynamics with Integra LifeSciences (PriMatrix, SurgiMend) and Smith+Nephew in advanced wound care
6. 06NovoSorb BTM sales for burns and trauma reconstruction (estimated 75-80% of revenue, primarily hospital direct sales)
7. 07Hernia repair products using NovoSorb technology (estimated 15-20%, emerging growth driver)
8. 08International distribution partnerships and licensing arrangements (estimated 5-10%)

CALZF Chart

My Notes

• growth - Investors are attracted to 23% revenue growth, 151% earnings growth, and early-stage profitability inflection in a large…
• Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples…
• Watch on earnings: US revenue growth rate quarter-over-quarter (indicates commercial execution in largest market), Gross margin percentage (any compression below 94% signals pricing pressure or manufacturing issues), Operating cash flow trend toward sustained positivity (validates business model scalability).